疱疹样脓疱病的治疗进展

doi:10.35541/cjd.20200609

Abstract

Abstract: 【Abstract】 Impetigo herpetiformis, also known as generalized pustular psoriasis of pregnancy, is generally considered as a rare subtype of pustular psoriasis that occurs during pregnancy. Current treatment includes systemic and topical glucocorticoids, cyclosporine, biologic agents, antibiotics, phototherapy, granulocyte and monocyte apheresis. This review summarizes treatment strategies for impetigo herpetiformis.

Key words: Psoriasis, Pregnant women, Glucocorticoids, Cyclosporine, Biological agents, Impetigo herpetiformis

Zou Meirong, Wang Sheng. Treatment of impetigo herpetiformis[J]. Chinese Journal of Dermatology, 2022, 55(10): 928-931.doi:10.35541/cjd.20200609

References ［24］

［1］	Fiboumi AE, Chiheb S. Impetigo herpetiformis: a rare dermotosis of pregnancy［J］. Pan Afr Med J, 2018,30:273. doi: 10.11604/pamj.2018.30.273.16424.
［2］	Tejeda CI, Voss V, Salvemini JN. Known history of pustular psoriasis with reactivation from in vitro fertilization therapy［J］. JAAD Case Rep, 2019,5（6）:543⁃545. doi: 10.1016/j.jdcr.2019. 04.005.
［3］	Namazi N, Dadkhahfar S. Impetigoherpetiformis: review of pathogenesis, complication, and treatment［J］. Dermatol Res Pract, 2018,2018:5801280. doi: 10.1155/2018/5801280.
［4］	Trivedi MK, Vaughn AR, Murase JE. Pustular psoriasis of pregnancy: current perspectives［J］. Int J Womens Health, 2018,10:109⁃115. doi: 10.2147/IJWH.S125784.
［5］	Hoegler KM, John AM, Handler MZ, et al. Generalized pustular psoriasis: a review and update on treatment［J］. J Eur Acad Dermatol Venereol, 2018,32（10）:1645⁃1651. doi: 10.1111/jdv. 14949.
［6］	Robinson A, Van Voorhees AS, Hsu S, et al. Treatment of pustular psoriasis: from the Medical Board of the National Psoriasis Foundation［J］. J Am Acad Dermatol, 2012,67（2）:279⁃288. doi: 10.1016/j.jaad.2011.01.032.
［7］	Chhabra G, Chanana C, Verma P, et al. Impetigo herpetiformis responsive to secukinumab［J］. Dermatol Ther, 2019,32（5）:e13040. doi: 10.1111/dth.13040.
［8］	Yamashita T, Hamada T, Maruta Y, et al. An effective and promising treatment with adalimumab for impetigo herpetiformis with postpartum flare⁃up［J］. Int J Dermatol, 2019,58（3）:350⁃353. doi: 10.1111/ijd.14141.
［9］	Ogrum A, Takci Z, Seckin HY, et al. Treatment resistant impetigo herpetiformis treated with infliximab［J］. Dermatol Ther, 2019,32（2）:e12839. doi: 10.1111/dth.12839.
［10］	Babuna Kobaner G, PolatEkinci A. Infliximab for the treatment of recalcitrant generalized pustular psoriasis of pregnancy: report of a challenging case［J］. Dermatol Ther, 2020,33（4）:e13571. doi: 10.1111/dth.13571.
［11］	Burmester GR, Landewé R, Genovese MC, et al. Adalimumab long⁃term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis［J］. Ann Rheum Dis, 2017,76（2）:414⁃417. doi: 10.1136/annrheumdis⁃2016⁃209322.
［12］	Flynn A, Burke N, Byrne B, et al. Two case reports of generalized pustular psoriasis of pregnancy: different outcomes［J］. Obstet Med, 2016,9（2）:55⁃59. doi: 10.1177/1753495X15626623.
［13］	Gordon KB, Warren RB, Gottlieb AB, et al. Long⁃term efficacy of certolizumabpegol for the treatment of plaque psoriasis: 3⁃year results from two randomized phase Ⅲ trials （CIMPASI⁃1 and CIMPASI⁃2）［J］. Br J Dermatol, 2020. doi: 10.1111/bjd.19393.
［14］	Mariette X, Förger F, Abraham B, et al. Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study［J］. Ann Rheum Dis, 2018,77（2）:228⁃233. doi: 10.1136/annrheumdis⁃ 2017⁃212196.
［15］	Liu N, Zhu L, Cheng Y, et al. Successful treatment of recurrent pustular psoriasis of pregnancy with secukinumab: a case report［J］. Acta Derm Venereol, 2020,100（15）:adv00251. doi: 10.2340/ 00015555⁃3611.
［16］	Mizutani Y, Mizutani YH, Matsuyama K, et al. Generalized pustular psoriasis in pregnancy, successfully treated with certolizumabpegol［J］. J Dermatol, 2020,47（7）:e262⁃e263. doi: 10.1111/1346⁃8138.15355.
［17］	Warren RB, Reich K, Langley RG, et al. Secukinumab in pregnancy: outcomes in psoriasis, psoriatic arthritis and ankylosing spondylitis from the global safety database［J］. Br J Dermatol, 2018,179（5）:1205⁃1207. doi: 10.1111/bjd.16901.
［18］	Kinoshita M, Ogawa Y, Takeichi T, et al. Impetigo herpetiformis with IL⁃36RN mutation successfully treated with secukinumab［J］. Eur J Dermatol, 2018,28（3）:381⁃382. doi: 10.1684/ejd. 2018.3259.
［19］	Alsenaid A, Prinz JC. Inadvertent pregnancy during ustekinumab therapy in a patient with plaque psoriasis and impetigo herpetiformis［J］. J Eur Acad Dermatol Venereol, 2016,30（3）:488⁃490. doi: 10.1111/jdv.12872.
［20］	Mizutani Y, Fujii K, Kawamura M, et al. Intensive granulocyte and monocyte adsorption apheresis for generalized pustular psoriasis［J］. J Dermatol, 2020,47（11）:1326⁃1329. doi: 10.1111/1346⁃8138.15569.
［21］	Fujii K, Takahashi T, Matsuyama K, et al. Impetigo herpetiformis with a CARD14 Thr79Ile variant successfully treated with granulocyte and monocyte adsorption apheresis［J］. J Dermatol, 2020,47（3）:e84⁃e85. doi: 10.1111/1346⁃8138.15241.
［22］	Saito⁃Sasaki N, Izu K, Sawada Y, et al. Impetigo herpetiformis complicated with intrauterine growth restriction treated successfully with granulocyte and monocyte apheresis［J］. Acta Derm Venereol, 2017,97（3）:410⁃411. doi: 10.2340/00015555⁃2527.
［23］	Luewan S, Sirichotiyakul S, Tongsong T. Recurrent impetigo herpetiformis successfully treated with methotrexate: a case report［J］. J ObstetGynaecol Res, 2011,37（6）:661⁃663. doi: 10. 1111/j.1447⁃0756.2010.01418.x.
［24］	Cravo M, Vieira R, Tellechea O, et al. Recurrent impetigo herpetiformis successfully treated with methotrexate［J］. J Eur Acad Dermatol Venereol, 2009,23（3）:336⁃337. doi: 10.1111/j.1468⁃3083.2008.02867.x.

[1]	Zhou Xue, Yu Zengyang, Chen Youdong, Guo Chunyuan, Yu Qian, Hu Yifan, Yao Lingling, Shi Yuling, . Tumor necrosis factor α-mediated low expression of fatty acid desaturase 2 in psoriasis [J]. Chinese Journal of Dermatology, 2022, 55(9): 752-758.
[2]	Yao Lingling, Yu Zengyang, Guo Chunyuan, Zhou Jing, Cui Lian, Yu Qian, Yu Yingyuan, Zhou Xue, Cai Jiangluyi, Shi Yuling, . Changes in circadian gene cryptochrome 2 expression in mouse models of psoriasis and HaCaT cells and their underlying mechanisms [J]. Chinese Journal of Dermatology, 2022, 55(9): 759-766.
[3]	Yu Chen, Wang Gang. Small-molecule targeted agents: new choices for the treatment of psoriasis [J]. Chinese Journal of Dermatology, 2022, 55(9): 747-751.
[4]	Xiao Chunying, Wang Gang. Roles of Langerhans cells in psoriasis [J]. Chinese Journal of Dermatology, 2022, 55(9): 830-834.
[5]	Sun Jie, Wang Rui, Li Chengxin. Tumor necrosis factor-α inhibitor?induced psoriasis [J]. Chinese Journal of Dermatology, 2022, 55(9): 821-824.
[6]	Liu Jin, Shen Zhengyu. Epigenetic regulation in psoriasis [J]. Chinese Journal of Dermatology, 2022, 55(9): 825-829.
[7]	Zheng Jiayuan, Yu Bingqian, Chen Xianxia, Luo Zhicheng. Characteristics of pruritus in adult patients with psoriasis vulgaris and its effect on quality of life [J]. Chinese Journal of Dermatology, 2022, 55(9): 790-794.
[8]	Fan Birao, Chen Xixue, Wang Mingyue. Retrospective analysis of efficacy and safety of minocycline alone or in combination with low-dose glucocorticoids in the treatment of 15 cases of pemphigus erythematosus and 9 cases of pemphigus herpetiformis [J]. Chinese Journal of Dermatology, 2022, 55(8): 676-681.
[9]	Jin Liang, Liu Ling. Treatment of some genodermatoses [J]. Chinese Journal of Dermatology, 2022, 55(8): 735-739.
[10]	Gao Zirui, Zhao Pei, Dou Yuanqing, Liu Ping, Zhang Jianzhong. Efficacy and safety of dupilumab in the treatment of adult prurigo nodularis [J]. Chinese Journal of Dermatology, 2022, 55(7): 562-565.
[11]	Wang Lingyan, Pan Jing, Miao Gang, Chang Xiaodan, Jin Qiuzi, Guo Ningning, Zhang Jiayu. Analysis of difficult-to-treat sites in patients with psoriasis who received biological therapy [J]. Chinese Journal of Dermatology, 2022, 55(7): 583-587.
[12]	Working Group for Atopic Dermatitis, Chinese Society of Dermatology, Working Group for Children′s Diseases, Chinese Society of Dermatology. Treatment of atopic dermatitis with dupilumab: an expert consensus [J]. Chinese Journal of Dermatology, 2022, 55(6): 465-470.
[13]	Committee on Autoimmune Diseases, China Dermatologist Association. Cyclosporine in the treatment of immune-related skin diseases: an expert proposal [J]. Chinese Journal of Dermatology, 2022, 55(6): 471-479.
[14]	Zhao Liuqi, Chen Yan, Chen Danyang, Fan Birao, Wang Rui, Shang Panpan, Chen Xixue, Zhu Xuejun, Wang Mingyue. Efficacy and safety of dupilumab in the treatment of 21 cases of bullous pemphigoid: a retrospective study [J]. Chinese Journal of Dermatology, 2022, 55(6): 480-485.
[15]	Huang Xin, Chen Xiaoyun, Li Yaping, Liang Xingkun, Zhang Guiying, Zhou Ying, Zhan Yi, Luo Shuaihantian, Liao Jieyue, Xiao Rong, Long Hai. Efficacy and safety of dupilumab in the treatment of 123 cases of atopic dermatitis [J]. Chinese Journal of Dermatology, 2022, 55(6): 486-493.

Treatment of impetigo herpetiformis

PDF

PDF (Mobile)

Knowledge

Abstract

Cite this article

share this article

References ［24］

Related Articles 15

Metrics

Comments

Recommended 10